Track market-moving stories before they get noisy

In an era where data is the new oil and security is the vault, choosing between CrowdStrike (CRWD 0.21%) and Snowflake (SNOW 0.40%) represents a classic debate for growth investors. Both companies sit at the center of modern digital transformation, yet they serve very different roles in the enterprise software ecosystem. This comparison explores which stock is a better buy today.

CrowdStrike focuses on stopping breaches through its AI-driven Falcon platform, securing the devices where work happens. Snowflake offers a platform that breaks down data silos, enabling companies to manage and analyze data for artificial intelligence applications. These two are often compared because they both represent high-growth, cloud-native leaders competing for the same IT budget dollars.

The case for CrowdStrikeCrowdStrike provides cloud-native cybersecurity through its Falcon platform, which protects endpoints, identity, and data for over 88,000 organizations. The company has built a dominant reputation among tech stocks by replacing legacy antivirus software with its integrated, AI-powered security architecture. Strategic technology alliances remain central to growth, including recent partnerships with Schwarz Digits and Grant Thornton Advisors.

In FY 2026, revenue reached nearly $4.8 billion, representing a growth rate of approximately 21.7% compared to the prior year. The company reported a net loss of roughly $162.5 million for the year. This resulted in a net margin of approximately -3.4%, up from the -0.5% reported in the previous fiscal year.

As of its January 2026 balance sheet, the debt-to-equity ratio is approximately 0.2x. This ratio measures total debt relative to shareholder equity, with lower numbers indicating less reliance on borrowed money. The current ratio stands at approximately 1.8x, which measures a company's ability to cover its short-term debts with its short-term assets. Free cash flow, which is cash from operations minus capital expenditures, reached nearly $1.3 billion. Note that stock-based compensation accounted for roughly 68.0% of operating cash flow, thereby inflating reported cash generation, since SBC is a non-cash expense added back in the cash flow statement.

The case for SnowflakeSnowflake provides the AI Data Cloud, a platform for data engineering, analytics, and AI applications. As of January 2026, the company served over 13,000 total customers across diverse industries, including healthcare and financial services. Its strategy relies on the Snowflake Partner Network and dependencies on major cloud infrastructure providers like Amazon (AMZN 0.91%), Microsoft (MSFT 1.67%), and Alphabet (GOOG 2.17%) (GOOGL 2.05%).

In FY 2026, revenue reached close to $4.7 billion, an increase of roughly 29.2% over the previous year. Despite this growth, the company reported a net loss of approximately $1.3 billion for the period. This performance resulted in a net margin of nearly -28.4%, an improvement from the -35.5% net margin seen in FY 2025.

As of its January 2026 balance sheet, the debt-to-equity ratio reached approximately 1.4x. A ratio of 1.4x indicates that the company uses more debt than equity to fund operations. The current ratio of roughly 1.3x suggests the company maintains enough liquid assets to meet its immediate financial obligations. Free cash flow for the year reached approximately $1.1 billion. Note that stock-based compensation represented roughly 130.9% of operating cash flow, meaning reported cash generation is heavily inflated by this non-cash add-back.

Risk profile comparisonCrowdStrike faces ongoing risks following the July 19 incident, which continues to impact its reputation, customer renewals, and business operations. The company is currently managing multiple securities class action lawsuits and derivative litigation stemming from that event. Furthermore, intense competition from legacy antivirus and newer cloud vendors requires constant innovation in artificial intelligence to maintain market share.

Snowflake faces significant exposure to security breaches, including incidents involving customer account access under the shared responsibility model. The company also faces heavy competition from its own infrastructure hosts, such as Amazon and Microsoft, which offer competing data solutions. Additionally, its consumption-based revenue model creates fluctuations in financial results based on how much data customers actually use each month.

Valuation comparisonSnowflake currently trades at a lower P/S ratio than CrowdStrike, though both maintain high forward P/E multiples.

MetricCrowdStrikeSnowflakeSector BenchmarkForward P/E165.5x138.5x338.0xP/S ratio43.1x19.8xn/aSector benchmark uses the SPDR XLK sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Both of these companies are benefiting from the growth of artificial intelligence, but in different ways. There are many opportunities to jump on the AI bandwagon, but between these two compelling choices, which is the better investment?

CrowdStrike’s cybersecurity subscription model produces consistent recurring revenue. Its customer base includes over 88,000 organizations, and its AI-enhanced security services are continually evolving, so there’s little incentive for these customers to go elsewhere. It has been growing steadily, reporting strong cash flow, generally accepted accounting principles (GAAP) profitability, and rewarding shareholders.

By comparison, Snowflake’s focus is on storage and analysis of the enormous amounts of information its clients can generate. This makes it a natural foundation for many AI applications. Rather than using CrowdStrike’s subscription model, Snowflake’s customers pay based on usage. The advantage of this model is that, as AI workloads increase, so can the company’s revenue. The company is currently unprofitable, however, and results are more dependent on fluctuations in customer usage.

Both stocks trade at premium valuations, so this isn’t a relevant basis for comparison. So, if I had to choose one of these companies for my portfolio, I would lean toward CrowdStrike. Its recurring revenue model and steady profitability make it a better AI play for 2026.

HomeStock IdeasLong IdeasConsumer Staples Analysis

SummaryEnergizer Holdings is rated a buy, trading at 5.94x forward earnings versus its 5-year average of 9.20x.I expect ENR to re-rate as the market stops pricing in permanent impairment, supported by raised FY26 guidance and a clear path to low-40s gross margin by Q4.My probability-weighted target is $27 (+34%), with limited downside near $19.80, as trough multiples are already priced in.Key risks include missing Q4 gross margin targets and continued organic volume declines, which could shift base to bear case outcomes. JHVEPhoto/iStock Editorial via Getty Images

Energizer Holdings, Inc. (ENR) is a global manufacturer headquartered in St. Louis. It manufactures, markets and distributes majorly through two segments: Batteries and Lights ((B&L)) and Auto Care. The B&L segment constitutes roughly 73% of the sales and batteries are the

18 Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

New York, New York--(Newsfile Corp. - July 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Peabody Energy Corporation (NYSE: BTU) between October 14, 2024 to May 4, 2026, inclusive (the "Class Period"), of the important August 24, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Peabody Energy common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Peabody Energy class action, go to https://rosenlegal.com/cases/peabody-energy-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 24, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Peabody Energy's Centurion mine and the multitude of issues causing delays to the ramp-up and the return to full longwall production dates. On March 30, 2026, Peabody Energy issued a press release lowering guidance pertaining to Centurion mine's expected first quarter 2026 output ahead of Peabody Energy's full earnings release. In pertinent part, defendants announced that sales volume from the Centurion mine was expected to deliver approximately 250,000 tons in the first quarter due to mining commissioning challenges (compared to previous estimates of around 700,000 tons). When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Peabody Energy class action, go to https://rosenlegal.com/cases/peabody-energy-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305723

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© 2024 Getty Images / Getty Images News via Getty Images

If you bought YieldMax TSLA Option Income Strategy ETF (NYSEARCA:TSLY) for the double-digit yield, look at your account. The distributions landed. The share price did not follow Tesla up the mountain. That gap is the hidden cost, and it is bigger than the expense ratio.

What You’re Actually Paying TSLY is a synthetic covered-call fund on Tesla. It parks cash in Treasury bills, sells call options on TSLA, and hands the option premium back to you as distributions. That works when Tesla trades sideways. It quietly punishes you when Tesla runs.

Here is the receipt. Over the past year, Tesla stock is up 31.59%. TSLY is up 34.01% on a total-return basis, which sounds fine until you widen the window. Since TSLY’s inception in November 2022, the fund is up 55.36%. Over roughly the same stretch, TSLA is up 86.21% over five years. The share price alone tells the story: TSLY closed at $26.73 on July 10, 2026, while its $17.65 starting NAV starting NAV appears preserved on a total-return basis only because distributions are re-added. Strip out the distributions, and the share price has bled.

The fund’s public expense ratio is not disclosed in the current snapshot data, but YieldMax funds in this category typically carry elevated fees relative to holding the underlying directly (0.99% management fee, verify before publishing). Compare that to holding TSLA directly at brokerage cost of zero. Over a decade, that fee drag alone could compound into a meaningful haircut, and that is before the opportunity cost stacked on top.

The Part the Factsheet Doesn’t Highlight Look under the hood. As of April 30, 2026, TSLY held roughly $877 million in Treasury bills across five CUSIPs, plus a small pile of TSLA call options. That is your “Tesla exposure”: T-bills and a synthetic overlay. The fund also carries $84.8 million in liabilities against $922 million in assets, with net derivative positions running at -7.67% of net assets. When Tesla rallies past the strike, those short calls owe money, and the NAV takes the hit.

Then there is the distribution machine. TSLY paid $13.29 per share over the trailing 12 months, but the forward annualized run rate has compressed to $3.33. In 2024, monthly checks ran between $0.40 and $1.29. In 2026, they have shrunk to weekly payments mostly between $0.26 and $0.35, with one payout at just $0.0707. A meaningful slice of these distributions in prior years arrived as return of capital, meaning the fund handed you back your own money and called it yield. That is not tax-free forever. It lowers your cost basis and defers a bill.

The Cheaper Mirror The low-cost alternative is TSLA itself. Zero management fee at most brokers, no capped upside, no synthetic overlay, no weekly 1099 complexity. If income is the goal, a barbell of short-duration Treasuries (iShares 0-3 Month Treasury Bond ETF (NYSEARCA:SGOV) or SPDR Bloomberg 1-3 Month T-Bill ETF (NYSEARCA:BIL), both low-cost) plus a modest direct TSLA position replicates the fund’s actual balance sheet more transparently, at a fraction of the cost, and lets you keep the upside above whatever strike TSLY happens to be shorting that week. The trade-off is clear: you give up the automatic call-writing convenience and the headline yield figure.

What This Means for You The right question is: what did I give up to get that yield? If TSLY’s distributions have been landing in your account while its share price grinds lower and Tesla stock keeps making highs, you have already paid the hidden cost. Whether the yield is worth capped upside, NAV decay, and taxable return-of-capital is a decision to make with your eyes open, not the marketing sheet.

Contact [email protected] for any questions or corrections.

In October 2025, Mark Zuckerberg's Meta (META 2.79%) announced plans to build a 2-gigawatt data center. By July 2026, that data center's capacity had been upgraded to 5 gigawatts. Meta isn't the only company building huge data centers; Space Exploration Corporation (SPCX 5.41%) is leasing out AI computing power from what it calls Colossus I and Colossus II. Building these giant facilities is creating a huge tailwind for some far less technologically driven stocks, including Caterpillar (CAT +0.35%) and Eaton (ETN +0.94%).

Caterpillar's backlog is up by 79%! Caterpillar makes earth-moving equipment and provides on-site power generators. Both are important for building artificial intelligence data centers. They are massive structures, so Cat's construction equipment is in high demand. And the electricity these buildings use is an increasingly contentious issue, making on-site power that doesn't drain the grid a huge opportunity, as well. Cat is already benefiting, with revenues up 22% in the first quarter of 2026 and adjusted earnings higher by 30%.

Image source: Getty Images.

However, the really big number is Cat's backlog, which stands at a record $63 billion. That figure is up 79% compared to the first quarter of 2025. This is basically future revenue for the company. It may be a boring industrial stock, but Cat is benefiting mightily from the high-tech AI sector.

Today's Change

(

0.35

%) $

3.11

Current Price

$

880.28

Eaton's AI backlog is ramping up Eaton makes electrical products for power management. It sells the infrastructure that, basically, forms the foundation of an AI data center. The company's business has been benefiting for years from the shift toward electrification, but AI has been a huge new opportunity.

Today's Change

(

0.94

%) $

3.72

Current Price

$

399.99

For example, the company's Americas business division has seen its backlog grow by over 40% year over year, driven by demand for AI. Notably, order growth has expanded at a 60% clip. Eaton has been shedding older businesses to streamline its operations, which complicates the story somewhat. However, a strong backlog provides a fairly clear line of sight for future revenues and earnings. And given the benefits it is seeing from AI demand, Eaton looks well-positioned for future success.

There's one problem to consider Wall Street is so focused on AI today that companies like Caterpillar and Eaton aren't flying under the radar. Cat's price-to-earnings ratio is a lofty 45x, while Eaton's is 38x. Value investors won't be interested. Still, the race to build AI data centers doesn't look anywhere near over, so the good news could easily keep going for these industrial giants. If you think AI will continue to grow, you may want to take a deeper look at each one.

Lemonade (LMND +4.35%) stock isn't having a great year. The insurance technology company's stock is down 7% year-to-date after skyrocketing 341% between 2024 and 2025.

But I think it could reach $100 next year, implying a 40% increase from today's price. Here's why.

A different kind of insurance company When Lemonade opened its virtual doors just about a decade ago, it set out to create a different kind of insurance company. The two main ways it differentiates itself are its digital foundation and its status as a certified B-Corp, which means it has a social mission. It allows customers to donate some of their funds to nonprofits through its "giveback" program.

Image source: The Motley Fool.

That attracts a certain kind of customer, but these days it's a tech-first, artificial intelligence-driven business attracting hundreds of thousands of new users who are just looking for a better insurance experience.

Growth has been phenomenal over the 10 years Lemonade has been in business, and it's recently been accelerating. The 2026 first quarter was the 10th consecutive quarter of accelerating in-force premium (IFP), which measures the amount of policy premium "in force" at a given time and is the standard top-line metric for insurance companies. It increased 32% year over year in the first quarter. Revenue is growing even faster, up 71% in the quarter.

Today's Change

(

4.35

%) $

2.81

Current Price

$

67.38

The company added almost 600,000 new customers over the trailing 12 months, a 23% increase, to 3.1 million in the first quarter, and premium per customer was up 7% to $424, implying that its cross-sell strategy is working.

What will change in 2027? Since Lemonade has gotten its loss ratio under control, the stock has soared. Its next big goal is to become profitable, and it's getting closer. Management is guiding to adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) turning positive by the end of this year and net income turning positive next year.

If it can reach those goals, the stock is likely to reflect that, and it can continue to rise without becoming more expensive. Right now, Lemonade stock trades at 6.8 times trailing-12-month sales. If sales continue to grow at current rates, Lemonade stock can gain 70% without becoming more expensive. If it becomes profitable while maintaining high growth rates, it should easily surpass $100 next year.

Chubb (CB +2.46%), the world's largest publicly traded provider of property, supplemental health, and casualty insurance, is a reliable blue chip stock. It's based in Switzerland, and it does business across 54 countries and territories. The current version of the company was created in 2016 after ACE Limited acquired the original Chubb and inherited its brand.

Chubb's stock has rallied 172% over the past ten years. With reinvested dividends, it delivered a total return of 226%. But at $352, it trades at just 12 times trailing earnings, compared to the S&P 500's historically high multiple of 32. It also pays a forward yield of 1.2%. So is it an undervalued, defensive stock to buy today?

Image source: Getty Images.

How fast is Chubb growing? From 2016 to 2025, Chubb's revenue and EPS grew at CAGRs of 7% and 13%, respectively. That growth was initially driven by ACE's takeover of Chubb, which instantly made it a powerhouse in the property and casualty insurance market.

Chubb dominated the high-net-worth insurance market in the U.S., expanded in Asia, replaced its legacy systems with newer technology platforms, and reduced its exposure to weaker businesses rather than taking on bad risk. Its fixed-income portfolio also benefited from higher interest rates.

Today's Change

(

2.46

%) $

8.46

Current Price

$

352.16

From 2025 to 2028, analysts expect Chubb's revenue and EPS to grow at CAGRs of 5% and 7%, respectively. That growth should be driven by the expansion of its middle-market and small commercial accounts to curb its dependence on the softer corporate property market, its deeper push into life insurance across Asia, automated underwriting services, agentic AI upgrades, and the "rolling" of its older, lower-rate fixed income investments into newer, higher-yielding ones.

Chubb also recently raised its dividend for the 33 consecutive year and authorized a new $7.5 billion buyback (equivalent to 5.5% of its current market cap). Those confident moves suggest its core businesses will continue to generate plenty of excess cash for the foreseeable future.

Is it the right time to buy Chubb's stock? Chubb's scale, diversification, and tech-driven upgrades make it a smart stock to buy today. It has a wide moat and is well insulated from macro headwinds because its customers generally won't cancel their insurance policies to save a few dollars.

While Chubb isn't a high-growth play, it's a stable one that should generate reliable returns. That's probably why Berkshire Hathaway significantly increased its position in Chubb over the past three years, and why it still looks like a screaming bargain at these levels.

5.52K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in TER over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of investors in BlackRock, Inc. mutual funds, resulting from allegations that BlackRock may have issued materially misleading business information to the investing public. So What: If you purchased BlackRock mutual funds you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. T.

Shares of Intuitive Surgical (ISRG 14.22%) fell this past week on concerns that the robotic surgery leader's growth is slowing.

Image source: Intuitive Surgical.

Solid Q2 results Intuitive saw a 16% year-over-year rise in worldwide procedures in the second quarter. Procedures with its da Vinci robotic surgical platform rose 15%, while procedures with its Ion robotic-assisted platform for minimally invasive lung biopsies surged 36%.

Intuitive placed 468 da Vinci and 55 Ion systems during the quarter. That contributed to a 12% increase in Intuitive's da Vinci installed base to 11,710 systems and a 21% jump in its Ion installed base to 1,096 systems.

In all, Intuitive's revenue climbed 19% to $2.9 billion, driven by higher system leasing fees and sales of instruments and accessories.

Today's Change

(

-14.22

%) $

-57.22

Current Price

$

345.11

The robotic technology pioneer's adjusted net income, in turn, grew 25% to $1 billion, or $2.80 per share. That topped Wall Street's estimates, which had called for per-share profits of $2.50.

Intuitive's outlook indicates a slower pace of expansion Yet investors appeared to focus more on Intuitive's guidance for the second half of 2026.

Management sees worldwide da Vinci procedure growth at the midpoint of its previously issued range of 13.5% to 15.5%. By besting expectations in the second quarter and not raising its full-year guidance, Intuitive is essentially forecasting slower growth for the rest of the year.

Wall Street responded with multiple price target cuts for Intuitive's stock, and many investors decided to sell their shares.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends the following options: long January 2028 $520 calls on Intuitive Surgical and short January 2028 $530 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.

New York, New York--(Newsfile Corp. - July 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the "Class Period"), of the important July 27, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Zoetis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and touted growing market share, strong veterinarian adoption, and accelerating sales growth across Zoetis' flagship Companion Animal products and/or failed to disclose that: (1) veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis' Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305692

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - July 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of purchasers of securities of Hub Group, Inc. (NASDAQ: HUBG) between April 28, 2023 and May 11, 2026, inclusive (the "Class Period"), of the important August 28, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Hub Group securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Hub Group class action, go to https://rosenlegal.com/cases/hub-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that Hub Group's financial statements prepared for the periods from Q1 2023 to Q4 2024, including annual reports for 2023 and 2024, contained material misstatements-caused by the premature and incorrect recognition of certain transactions-concerning, inter alia, Hub Group's operating revenue, operating income, revenue recognition, effectiveness of internal controls and procedures, and drivers of financial results and growth. In addition, Hub Group's financial statements prepared for the periods from Q1 2025 to Q3 2025 contained material misstatements-caused by the understatement of purchased transportation costs and accounts payable -concerning, inter alia, Hub Group's operating expenses, purchased transportation and warehousing expenses, operating income, effectiveness of internal disclosure controls and procedures, and drivers of financial results and growth. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Hub Group class action, go to https://rosenlegal.com/cases/hub-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305701

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Wahid Nawabi, Chair, President and CEO of AeroVironment, Inc. (AVAV 4.75%), disposed of 5,246 shares of common stock on July 10, 2026, according to a recent SEC Form 4 filing.

Transaction summaryMetricValueTransaction value~$758,500Shares sold5,246Post-transaction shares (directly held)~162,200Post-transaction value$23.45 millionTransaction value based on SEC Form 4 weighted average sale price ($144.58); post-transaction value based on July 10, 2026, market close ($144.58).

Key questionsWhat triggered this stock disposition?
The sale was non-discretionary and was carried out solely to meet tax withholding requirements triggered by the vesting of previously granted restricted stock awards. This is a routine procedural event and does not represent a voluntary market sale or a change in the CEO's outlook on the company.What is the executive's current equity position in the company?
Following the tax settlement, Wahid Nawabi maintains direct ownership of ~162,200 shares. This remaining stake represents approximately 0.32% of the company's total outstanding shares and reflects a concentrated personal investment in the firm.What is the significance of the underlying vesting event?
The vesting of these restricted stock awards indicates the fulfillment of specific service or performance milestones within the company's equity incentive framework. While a portion of the vested shares was sold to cover mandatory taxes, the transaction ultimately supports the executive's long-term alignment with shareholders by increasing his total vested equity base.Company OverviewMetricValueShare Price (as of market close 2026-07-17)$142.20Market Capitalization$7.3 billionRevenue (TTM)$2.0 billionNet Income (TTM)-$265.1 millionCompany SnapshotAeroVironment develops, produces, and delivers a comprehensive portfolio of robotic systems and unmanned aircraft platforms, including Unmanned Aircraft Systems (UAS), Tactical Missile Systems (TMS), Medium Unmanned Aircraft Systems (MUAS), and High Altitude Pseudo-Satellite Systems (HAPS), generating revenue through both product sales and ongoing support services.The company operates on a defense-oriented business model, providing specialized robotic and autonomous systems to governmental agencies and commercial entities, with revenue derived from product development, manufacturing, system integration, and long-term customer support contracts.AeroVironment's primary customer base consists of U.S. government agencies and international defense departments, supplemented by commercial clients seeking advanced unmanned systems for surveillance, reconnaissance, and tactical applications.AeroVironment is a leading provider of unmanned systems and robotic platforms serving the aerospace and defense sector, with a market capitalization of $7.3 billion and TTM revenues of $2.0 billion. The company maintains a diversified product portfolio across multiple unmanned platform categories, positioning itself as a critical supplier to government and commercial customers requiring advanced autonomous and remote-operated systems. Despite current operational losses, AeroVironment's strategic focus on high-growth defense markets and emerging autonomous technologies underscores its competitive positioning within the industrial aerospace and defense landscape.

What this transaction means for investorsNawabi’s sales are merely done to cover his tax withholdings from his restricted stock units, so the sale itself is nothing for investors to worry about. As for AVAV stock itself, its 50% share price plunge over the last year probably seems a bit more worrying.

However, I don’t believe we are anywhere near needing to panic over things just yet. Rather, I’d argue that AeroVironment’s valuation probably got a bit out over its skis in the last couple of years and is now potentially attractively priced, with its price-to-sales ratio of 3.5 near its 10-year lows. The company grew sales by 40% in its latest quarter, saw its funded backlog grow by 82% in 2025, and expects revenue to grow between 15% and 20% through 2030.

With the U.S. government leaning into drones and similar UAS solutions for defense, I don’t believe this growth is temporary by any means -- but anything is possible when dealing with the government. As AeroVironment transforms from simply a drone/UAS maker into a fully integrated defense platform following the acquisition of Blue Halo and its space operations and software foundation layer, AVAV will remain on my shortlist and is likely to grow from a starter position into a full holding.

Josh Kohn-Lindquist has positions in AeroVironment. The Motley Fool has positions in and recommends AeroVironment. The Motley Fool has a disclosure policy.

NEW YORK, July 18, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Verra Mobility Corporation (NASDAQ: VRRM) between February 24, 2026 and May 26, 2026, inclusive (the “Class Period”), of the important August 4, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Verra common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Verra class action, go to https://rosenlegal.com/cases/verra-mobility-corporation-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 4, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Verra’s relationship with Avis Budget Group (“Avis”), and in particular obtaining a contract extension with Avis. Further, Verra minimized concerns that major rent-a-cars could replace Verra with in-house solutions or outsourced alternatives. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Verra class action, go to https://rosenlegal.com/cases/verra-mobility-corporation-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Milliseconds matter on Wall Street, and Truth Social wants to charge traders to get faster access to the president's posts.

In a move that could help validate SpaceX’s (SPCX 5.43%) enormous investment in artificial intelligence (AI), the company is reportedly discussing a multi-billion-dollar computing contract with the Department of Defense (DOD), as originally reported by The Wall Street Journal.

The terms of the agreement, while not yet confirmed by the Pentagon or SpaceX, would allow the Defense Department to use SpaceX’s data centers to run AI models. This could follow similar deals SpaceX has inked with Alphabet (NASDAQ:GOOG) and Anthropic, and place it among an exclusive group of cloud-computing providers that are supporting the Pentagon’s AI operations.

Although the deal remains tentative and, in The Journal’s words, “could fall apart,” the development may reveal something important for SpaceX investors. Let’s take a closer look.

Image source: The Motley Fool.

Why investors should pay close attention to this deal To really understand the significance of this deal, we should step back and remember how closely SpaceX’s future is now tied to artificial intelligence.

Until Feb. 2, 2026, SpaceX was best known for launching rockets and managing its satellite-based internet service, Starlink. But in early February, SpaceX acquired xAI, forming a massive entity that’s now valued at about $1.6 trillion.

The acquisition not only brought two of Elon Musk’s businesses under the same roof but also provided xAI with a larger capital base to help it scale faster. The idea is that eventually, the AI business will become SpaceX’s major growth engine, even if it’s burning cash right now. Indeed, in SpaceX’s pre-IPO roadside show, the company claimed AI will unlock a $26.5 trillion market opportunity, whereas the market opportunity for the other two businesses is about $2 trillion.

Here’s the kicker, however: xAI generated an operating loss of about $6.4 billion in 2025. Although the rest of SpaceX’s operations helped offset some of that damage, the company still posted a net loss of about $4.9 billion for the year.

Today's Change

(

-5.43

%) $

-7.12

Current Price

$

123.99

This is where the potential deal with the Pentagon comes in. If the Pentagon becomes a multi-billion-dollar customer, SpaceX’s AI segment could start carrying some of the financial load investors expect it to shoulder. At the very least, it could help offset this segment’s heavy losses, bringing the space company closer to profitability.

And this isn’t just any old customer, either. This is the DOD, a government agency. Once SpaceX is approved to handle its workloads, which, mind you, could contain sensitive or classified information, walking away from it won’t be easy, nor will it be cheap. Indeed, the high switching costs alone could turn this contract into a pretty durable, long-term revenue stream -- one that could increase in value if the agency decides to purchase more computing power over time.

Does the deal with the Pentagon make SpaceX a screaming buy right now? I wouldn’t call SpaceX a screaming buy right now, nor even a murmuring one. And it has everything to do with SpaceX’s valuation right now.

The stock has been trading at a premium since its mid-June market debut. It currently trades more than 40% below its all-time high; even so, SpaceX trades at more than 80 times sales.

At the end of the day, SpaceX investors are being asked to believe in many things that seem outlandish at first glance. Lunar settlements, missions to Mars, orbital data centers. Some of these ambitions may eventually materialize; others could remain fantasies. For now, I would continue watching SpaceX from the sidelines, at least until its valuation comes back down to earth. 

July 18, 2026 15:15 ET  | Source: 4D Molecular Therapeutics, Inc.

After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well tolerated with no new safety or intraocular inflammation findings EMERYVILLE, Calif., July 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced positive 2-year data from the PRISM Phase 2b clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration (wet AMD) population. The data were presented by Carl Awh, M.D., FASRS, Tennessee Retina, in an oral presentation titled “2-Year Follow Up: PRISM Phase 2b Clinical Trial Evaluating Investigational 4D-150, an Intravitreal Gene Therapy, in a Broad Neovascular AMD Population” at the 44th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS).

2-Year Data from PRISM Phase 2b Clinical Trial (Data Cutoff May 18, 2026):

Trial and Patient Cohort Overview

The Phase 2b trial enrolled 45 patients at two dose levels of a single intravitreal dose of 4D-150 (3E10 and 1E10 vg/eye); 3E10 vg/eye was chosen as the dose for the 4FRONT Phase 3 clinical trialsThe Phase 2b overall cohort enrolled patients with broad disease activity (n=30 dosed with 3E10 vg/eye and n=15 dosed with 1E10 vg/eye)The Phase 2b cohort subgroup comprised recently diagnosed patients (diagnosed within 6 months, n=15 at 3E10 vg/eye), which is most comparable to the population enrolled in the 4FRONT Phase 3 clinical trials Phase 2b Efficacy Results Through 2 Years:

Consistent maintenance of best corrected visual acuity (BCVA)Consistent control of central subfield thickness (CST) as measured by optical coherence tomographyConsistent, durable and clinically meaningful reduction in treatment burden: Overall cohort: 78% overall treatment burden reduction (2.7 mean supplemental injections per patient vs. 12.0 injections projected with on-label aflibercept 2 mg Q8W) Recently diagnosed subgroup: 87% overall treatment burden reduction (1.6 mean supplemental injections per patient vs. 12.0 injections projected with on-label aflibercept 2 mg Q8W) Dose response maintained throughout 2 years in favor of the Phase 3 dose Safety Data for Phase 3 Dose in Overall PRISM Phase 1/2a & 2b Clinical Trial (n=71)

4D-150 continues to be well tolerated: Intraocular inflammation: As previously reported, within approximately the first 6 months (28 weeks) post-4D-150 dosing, 2.8% (2 of 71) of patients had 4D-150-related 1+ (mild) intraocular inflammation (IOI) (SUN/NEI scales), which were transient 1+ vitreous cells noted at a single timepointFollowing the first 28 weeks post-4D-150 dosing, no new cases of inflammation with 2 to more than 4 years of follow-up on all patients as of the data cutoff No 4D-150-related hypotony, endophthalmitis, vasculitis, occlusive/non-occlusive retinal vasculitis or choroidal effusions observed to date “Two-year PRISM data continue to strengthen our conviction in 4D-150’s potential to become a foundational backbone therapy for wet AMD,” said David Kirn, M.D., Co-founder, President, and Chief Executive Officer of 4DMT. “The continued consistency in visual acuity and anatomic control with meaningful reduction in treatment burden and long-term tolerability reinforces our confidence in delivering a transformative treatment option for retina specialists and their patients.”

“For retina specialists and our patients, maintaining the intensive injection schedule necessary to preserve vision is a tremendous challenge,” said Carl Awh, M.D., FASRS, Tennessee Retina. “The two-year PRISM results demonstrate the potential of a single intravitreal administration of 4D-150 to provide long-term anti-VEGF and sustained disease control. Reducing treatment burden will undoubtedly improve our ability to preserve vision over the long term for our patients.”

The presentation from ASRS is available on the 4DMT website under Scientific Presentations.

About 4D-150

4D-150 is a potential backbone therapy designed to provide multi-year, and potentially lifelong, sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) within the retina following a single intravitreal injection. 4D-150 utilizes our customized and evolved intravitreal AAV vector, R100, which was invented at 4DMT through our proprietary Therapeutic Vector Evolution platform. 4D-150 is being developed for wet AMD and diabetic macular edema (DME), which both affect millions of patients globally, with the goal of freeing patients from burdensome injections while preserving vision.

About Wet AMD

Wet AMD, or wet age-related macular degeneration, is a highly prevalent disease, with more than 4 million individuals expected to be affected in the next five years in certain major markets, including the U.S., the EU and Japan. The disease also has a high incidence, with 200,000 individuals estimated to be newly diagnosed every year in the U.S. alone. Wet AMD is a type of macular degeneration in which abnormal blood vessels grow into the macula (macular neovascularization or MNV), the central area of the retina. MNV causes swelling and edema of the retina, bleeding and scarring, leading to visual distortion and reduced visual acuity. The proliferation and leakage of abnormal blood vessels is stimulated by VEGF. This process distorts and, without treatment, can potentially destroy central vision and may progress to blindness.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™ and the 4DMT logo are trademarks of 4DMT.

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn. 

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the therapeutic potential, treatment-burden reduction, durability, clinical development plans, regulatory timing, and success of clinical trials for 4D-150. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including risks and uncertainties that are described in greater detail in the section entitled “Risk Factors” in 4D Molecular Therapeutics’ most recent Quarterly Report on Form 10-Q filed on May 7, 2026, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics' current views and should not be relied upon as representing its views as of any subsequent time. 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Contacts:

Media:
Jenn Gordon
dna Communications
[email protected]

Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
[email protected]

The market got great news from the big banks this week. All five of the largest U.S. banks reported second-quarter earnings on Tuesday, and they were almost uniformly outstanding. But although the U.S. consumer appears healthy, it was market-related activity like initial public offerings (IPOs) that really stood out.

JPMorgan Chase (JPM 0.44%) and Goldman Sachs (GS 2.76%) led the earnings parade as the two top investment banks in the country, and these divisions drove high growth in the quarter; investment banking revenue increased 45% year over year at JPMorgan Chase and 55% at Goldman Sachs.

CEOs at both banks said they see more opportunity around the corner, with artificial intelligence (AI) playing a big role. In fact, JPMorgan Chase CEO Jamie Dimon said he thinks AI spend is going to reach $1 trillion next year.

JPMorgan Chase CEO Jamie Dimon. Image source: JPMorgan Chase.

On the second-quarter earnings call, Dimon posited that total capital expenditure is about $4 trillion, with AI representing a massive amount. "AI went from $400 billion last year to $700 billion this year," he said. "People project, which so do our people, it will be like a little over a trillion next year and maybe a little reduction in the non-AI capex."

That implies that in 2027, AI spend will account for more than a quarter of all company spend.

Today's Change

(

-0.44

%) $

-1.52

Current Price

$

341.63

He also cautioned that even though the current market is "getting close to as good as it gets," investors shouldn't forget the most important thing: "We just don't know how long it's going to last."

In the near term, though, the AI party is going strong, and investors can look forward to more expansion and matching stock prices.

JPMorgan Chase is an advertising partner of Motley Fool Money. Jennifer Saibil has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group and JPMorgan Chase. The Motley Fool has a disclosure policy.

Blockmate Ventures Inc (TSX-V:MATE, OTCQB:MATEF, FRA:8MH) chairman Domenic Carosa talked with Proactive about the company’s recently completed C$1 million capital raise and how the funds will support its Wyoming AI Data Center project.

Carosa said the capital would be used to advance work on the proposed facility. The company’s directors also participated in the financing, representing 29% of the capital invested in the announced raise. He said the directors’ participation reflected the group’s belief in the project.

Proactive: Hello, you’re watching Proactive. I’m joined by Blockmate Ventures Inc (TSX-V:MATE, OTCQB:MATEF) chairman Domenic Carosa. Dom, it’s very good to speak with you. You’ve raised C$1 million, well above target. How are you going to use the money, and why did the directors invest so heavily?

Domenic Carosa: Thanks for having me today. We have just completed a C$1 million raise. The capital will be used to further advance our Wyoming AI Data Center facility, which we are continuing to work on.

The directors believe in the project, and we have all invested as well. The directors represent 29% of the capital invested in the financing announced today.

What is the latest on the Wyoming AI Data Center, and what are the key milestones investors should watch for next?

Our objective over the next six to 12 months is to reach what is called “shovel-ready” status.

We are currently in discussions with a number of potential partners, including hyperscalers and neoclouds. These are effectively the groups that could potentially take over the facility once it is built.

We are also in the middle of a process with the local city regarding zoning and the rezoning of part of the land. The site covers approximately 100 acres in total, for those who have seen the presentation deck, and we are working to secure the appropriate zoning for it.

You have just been on an investor roadshow in Vancouver, and you are heading to Toronto next week. What questions are investors asking most, and what do you think they are still missing about the Blockmate story?

I think it is primarily an issue of exposure. Of the investors we spoke with in Vancouver a couple of weeks ago, not many had heard of Blockmate Ventures or what the company is doing in the sector.

The roadshow is therefore about getting the company’s message and story out to the market. As we said earlier this year, we are making a significant commitment in 2026 to communicate the story more actively.

My view is that we did not do that as effectively as we should have in 2025. I think investors have already started to see significant progress in how we communicate with the market and in the company becoming more visible.

Frankly, the more investors know about the Blockmate story, the better.

Are you seeing increasing interest in the company?

I think that is reflected in how quickly we were able to open and close the capital raise.

A number of institutional investors and high-net-worth investors participated in this round. We are very pleased with that support, as well as the support shown by the directors.

Now, it is all about execution. We know what we need to do. As we say in Australia, it is “head down, bum up,” which means we simply get on with the job.

I hope you will keep us posted as you get on with the job. Thank you very much for your time today.

Thank you.

Domenic Carosa, chairman of Blockmate Ventures Inc.

Quotes have been lightly edited for clarity and style

Space Exploration Technologies (SPCX 5.41%), AMD (AMD 0.66%), and Palantir Technologies (PLTR 1.53%) may seem like an odd grouping of companies. But I have a good reason to consider them together: They're all incredibly overvalued.

While that may sound like a shocking statement, after digging into each stock, that's the reality, and investors sitting on them may want to consider swapping them out of their portfolios for some more reasonably valued counterparts in their industries.

So, just how pricey are they? Let's take a look.

Image source: Getty Images.

Although SpaceX just went public a few weeks ago, I think it's one of the most overvalued stocks on the market. But that's only if you value the company based on what it has already done.

The majority of SpaceX investors are buying into the stock because of what it could achieve under Elon Musk's leadership. That's a fair investment thesis, and it's what has allowed Tesla to remain one of the largest companies in the world despite its business struggles over the past few quarters. If that's your angle, I'm not going to argue, but it doesn't alter the fact that SpaceX's business as it stands now does not justify the company's valuation.

Today's Change

(

-5.41

%) $

-7.09

Current Price

$

124.02

SpaceX hasn't reported earnings results as a public company yet, so the only information investors have to go on is from its IPO presentation. According to that, in 2025, SpaceX generated $18.7 billion in revenue and reported negative net income. So if we value the company using 2025 sales, that would price SpaceX at 92 times sales.

Even if SpaceX could snap its fingers and become instantly profitable with a 45% profit margin (its stated long-term goal), that would value the stock at 204 times earnings. That's an incredibly expensive stock, and with 2025 revenue growth coming in at only 33%, those numbers don't jibe.

That's not to say SpaceX cannot overcome this with future growth, but even then, a lot of hoped-for growth is already priced into the stock, so I'm avoiding it.

AMD AMD stock has risen by about 150% so far in 2026. While some of that gain was earned, the rest of it is a real head-scratcher.

AMD is constantly compared to Nvidia, as these two compete against each other in many product lines, but the most important arena for both right now is the data center market. Nvidia's data center division is far larger and growing much faster than AMD's, which makes it odd that AMD is now valued at such a premium to Nvidia.

NVDA PE Ratio (Forward) data by YCharts.

With Nvidia's growth this fiscal year expected at 82% versus AMD's 43%, the justification for AMD's premium over Nvidia is a mystery. As a result, I think investors would be far better off selling AMD stock and scooping up Nvidia while it's as cheap as it is.

Palantir Technologies Lastly, there is Palantir, which has been a popular AI stock pick over the past year. Its business continues to excel, and it grew by a strong 85% in the past quarter.

But the problem is that a growth deceleration could be on the way. Wall Street estimates that Palantir's growth rate, which is projected to be 72% this year, will decline to about 45% next year.

Today's Change

(

-1.53

%) $

-2.06

Current Price

$

132.38

While that's still rapid, it's not enough to warrant the 90 times forward earnings valuation the stock carries. That's an expensive premium for any stock, even one growing as fast as it is today. If Palantir's growth rates start to decline at any time, the market could send its shares lower, as a ton of anticipated success is already priced into the stock.

That makes it a bit of a precarious investment, and I think there are far better AI stocks to invest in than Palantir right now.

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Intuit Inc. (“Intuit” or “the Company”) (NASDAQ: INTU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between August 22, 2025 and May 20, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before September 8, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Intuit overstated the strength and sustainability of its business as well as its competitive advantages. The Company was losing its market share in its Turbo Tax in particular due in part to pricing pressure. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Intuit, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Taylor Farms is a critical supplier to restaurants and retailers, with produce from a single processing facility often distributed to customers across multiple states.

The space economy has captured the spotlight this year, primarily driven by the highly anticipated initial public offering (IPO) of Space Exploration Technologies (SPCX 5.43%), better known as SpaceX. On June 12, the company made history with the largest initial public offering ever and closed the day with a valuation of around $2.1 trillion, putting it in the company of some of the world's largest companies.

That said, SpaceX doesn't have nearly the revenue of those behemoths and trades at an expensive valuation that prices in massive future growth, making the stock vulnerable to huge price swings. If you're an investor looking for exposure to the rapidly expanding space economy, here are two space stocks that are better buys before piling into SpaceX.

Image source: Getty Images.

Rocket Lab's business spans the space ecosystem Rocket Lab (RKLB +0.59%) is the biggest competitor to SpaceX's launch business and the second-most-used launch platform in the United States today. Over the past year and a half, Rocket Lab has made 35 launches, dwarfed by SpaceX's 260 over the same period. That said, Rocket Lab has carved out a niche with its small-lift Electron rocket, which enables it to serve small to medium-sized satellite customers.

Because its Electron rocket can carry payloads of only around 300 kilograms (660 lbs), Rocket Lab cannot currently carry large payloads into space like SpaceX can with its Falcon 9. However, its small rocket provides its customers with greater flexibility and control over the timeline while also enabling precise placement of these smaller satellites into orbit.

Today's Change

(

0.59

%) $

0.40

Current Price

$

67.75

In addition, Rocket Lab has developed the Hypersonic Accelerator Suborbital Test Electron (HASTE), a launch platform specifically designed for defense and national security purposes. The advantage of HASTE is that it provides the government with high-cadence, cost-effective testing for hypersonic and suborbital payloads as the Pentagon evaluates various defense technologies. In March, Rocket Lab secured a $190 million contract to conduct 20 hypersonic test flights for its HASTE launch vehicle.

Rocket Lab's launch services business continues to grow steadily, but the company has another avenue for growth through its space systems business. Here, Rocket Lab designs and manufactures a wide range of space components and technologies, such as satellite buses, reaction wheels, star trackers, solar panels, separation systems, radios, and software. Of its $2.2 billion backlog, $1.3 billion is related to its space systems segment.

SpaceX also owns xAI and other technology businesses, where it is pegging most of its future growth. For investors looking for a more pure-play space stock, Rocket Lab's end-to-end space business spans multiple verticals, and the company has made major acquisitions in recent years to expand its role in the space ecosystem.

Lockheed Martin is a prime contractor for NASA's Orion program Lockheed Martin (LMT 0.93%) is a massive defense contractor, with sales from aeronautics (notably its F-35 fighter jets and other military aircraft), missiles, rocket systems, and helicopters, as well as a growing space business. For investors seeking exposure to a more stable stock with ties to the space economy, Lockheed Martin is appealing.

The company's broad portfolio and position in the defense industry provide it with a strong competitive moat and a platform that translates into stable, long-term revenue. Its F-35 program is projected to generate $2.1 trillion over its 94-year lifecycle (from 1994 to 2088) and is a major part of its business, providing stability and buffering its earnings against recessions and economic volatility.

Today's Change

(

-0.93

%) $

-4.75

Current Price

$

508.77

However, its space segment is another key growth driver for its wide-ranging business. Here, Lockheed develops missile-warning satellites, GPS satellites, classified spacecraft, and next-generation missile defense systems. In addition, Lockheed Martin is the prime contractor for NASA's Orion spacecraft, responsible for designing, building, and assembling the capsule that will take astronauts to the Moon and beyond.

Compared with SpaceX, Lockheed offers investors a more diversified business that benefits from recurring revenue from decades-long space programs, providing direct exposure to growing U.S. and allied spending on space infrastructure and to soaring defense spending amid geopolitical uncertainty.

On top of that, the company trades at a far lower multiple and pays a solid dividend yielding 2.7%, which it has grown every year for the past 23 years. For more conservative investors seeking exposure to the growing space economy, Lockheed Martin is an excellent stock to buy today.

HomeDividends AnalysisDividend Strategy

SummaryI identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics, and inflation while generating attractive income.My "ALLKA Dividend Rating" model separates quality dividend opportunities from yield traps by analyzing dividend sustainability, growth prospects, and valuation.The article explores three dividend strategies, "High-Yield Defensive," "Balanced Income," and "Pure Growth," designed for goals ranging from high yield to dividend growth.I look beyond retirement favorites such as Realty Income [~5% yield] and Verizon [~6.5% yield], showing how investors can combine reliable income with sustainable growth. Deagreez/iStock via Getty Images

Brent and WTI crude futures (CO1:COM, CL1:COM) were up 17.2% and 15.3%, respectively, this week.

Meanwhile, the S&P VIX Index (VIX), or "fear index," rose 25% to 18.8.

As a result, I believe that dividend stocks

3.46K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of PAGS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Daniel J. Englander, Director at Copart, Inc. (CPRT 2.40%), reported a sale of 80,000 shares of common stock on July 13, 2026, according to an SEC Form 4 filing.

Transaction summaryMetricValueTransaction value$2.2 millionShares sold (indirectly held)80,000Post-transaction shares (indirectly held)510,704Post-transaction value$14.02 millionTransaction value based on SEC Form 4 weighted average sale price ($27.55); post-transaction value based on July 13, 2026, market close ($27.45).

Key questionsWhat was the execution methodology for this trade?
The shares were sold in multiple transactions at prices ranging from $27.50 to $27.66. The reported price of $27.55 reflects the weighted average of these executions.What is the nature of the insider's remaining equity position?
Daniel J. Englander holds no shares directly. His remaining interest consists of ~511,000 shares held indirectly through Ursula Capital Partners, representing a 0.0552% ownership stake in the company.Are there any other notable changes in the entity's holdings?
In addition to the open-market sale, the filing disclosed that Ursula Capital Partners distributed 40,000 shares to its limited partners on July 13, 2026, though the insider himself was excluded from this distribution.What is the company's current market position?
Copart operates as a global provider of online vehicle auctions with a market capitalization of $25.5 billion as of the July 14, 2026, market close. The firm generated $4.6 billion in trailing twelve-month revenue and $1.6 billion in net income over the same period.Company OverviewMetricValueShare Price (as of market close 2026-07-17)$27.61Market Capitalization$25.5 billionRevenue (TTM)$4.6 billionNet Income (TTM)$1.6 billionCompany SnapshotCopart operates a global online vehicle auction platform that enables buyers and sellers to transact vehicles through sophisticated virtual bidding technology, generating revenue from auction commissions, seller fees, and ancillary services across multiple international markets.The company's business model centers on providing comprehensive vehicle remarketing solutions that connect buyers and sellers in a digital marketplace, capturing transaction-based revenue while maintaining a capital-light operational structure.Copart serves a diverse customer base, including insurance companies, financial institutions, fleet operators, and individual vehicle owners across the United States, United Kingdom, Germany, Brazil, Canada, and the Middle East.Copart is a leading global provider of online vehicle auctions and remarketing services, with a market capitalization of $25.5 billion and TTM revenue of $4.6 billion. The company leverages proprietary digital infrastructure to facilitate vehicle transactions across 11 international markets, generating substantial net income of $1.6 billion on a TTM basis. With 11,600 employees globally, Copart maintains a competitive advantage through its scalable technology platform and established network of buyers and sellers, positioning itself as a critical infrastructure provider in the vehicle disposition and remarketing ecosystem.

What this transaction means for investorsEnglander’s 80,000-share sale doesn’t appear to be a needle-moving development for CPRT shareholders, as the director will still hold over 500,000 shares following the transaction. That said, the timing of the sale is unfortunate for Englander, as Copart is currently in the midst of a 40% drawdown over the last year.

However, following this decline, Copart is one of my favorite S&P 500 companies to buy on the dip right now. After unusually strong hurricane seasons artificially boosted the company’s sales figures in 2024 and 2025, Copart has struggled to sustain those results and has been punished heavily by the market. Sales and EPS in its most recent quarter only inched 2% higher. Now that former CEO Jay Adair is returning to the company as the top banana again, Copart looks to rebound from its current depressed state.

Home to the leading network of 250 salvage yards across North America, Copart is well-positioned to thrive over the longer term as total loss rates continue to soar, as insurers tend to increasingly balk at repairing the technology-dense components in today’s modern cars. Trading at just 17 times forward earnings -- despite averaging 15% annualized revenue growth over the last decade -- I think Copart looks like a compelling risk-reward proposition at today’s price.